Chronic erythropoietin treatment improves diet-induced glucose intolerance in rats.

J Endocrinol

Exercise Health and Performance Faculty of Health Sciences, and Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia Faculty of Health and Medical Sciences The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark Department of Neuroscience and Pharmacology Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark School of Medicine and Pharmacology Royal Perth Hospital, The University of Western Australia, Perth, Western Australia, Australia UMR CNRS 9214 U1046 INSERM Physiologie et Médecine Expérimentale du Cœur et des Muscles, Université de Montpellier, Montpellier, France Physiology Department CHU Arnaud de Villeneuve, Montpellier, France Department of Endocrinology Sydney Medical School, Royal Prince Alfred Hospital, University of Sydney, Camperdown, New South Wales, Australia Inflammation and Infection Research School of Medical Sciences, UNSW Australia, Sydney, New South Wales, Australia

Published: May 2015

Erythropoietin (EPO) ameliorates glucose metabolism through mechanisms not fully understood. In this study, we investigated the effect of EPO on glucose metabolism and insulin signaling in skeletal muscle. A 2-week EPO treatment of rats fed with a high-fat diet (HFD) improved fasting glucose levels and glucose tolerance, without altering total body weight or retroperitoneal fat mass. Concomitantly, EPO partially rescued insulin-stimulated AKT activation, reduced markers of oxidative stress, and restored heat-shock protein 72 expression in soleus muscles from HFD-fed rats. Incubation of skeletal muscle cell cultures with EPO failed to induce AKT phosphorylation and had no effect on glucose uptake or glycogen synthesis. We found that the EPO receptor gene was expressed in myotubes, but was undetectable in soleus. Together, our results indicate that EPO treatment improves glucose tolerance but does not directly activate the phosphorylation of AKT in muscle cells. We propose that the reduced systemic inflammation or oxidative stress that we observed after treatment with EPO could contribute to the improvement of whole-body glucose metabolism.

Download full-text PDF

Source
http://dx.doi.org/10.1530/JOE-15-0010DOI Listing

Publication Analysis

Top Keywords

glucose metabolism
12
treatment improves
8
glucose
8
epo
8
skeletal muscle
8
epo treatment
8
glucose tolerance
8
oxidative stress
8
chronic erythropoietin
4
treatment
4

Similar Publications

Novel Therapies for Right Ventricular Failure.

Curr Cardiol Rep

January 2025

Pediatric Advanced Heart Failure and Heart Transplant Program, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, USA.

Purpose Of Review: Traditionally viewed as a passive player in circulation, the right ventricle (RV) has become a pivotal force in hemodynamics. RV failure (RVF) is a recognized complication of primary cardiac and pulmonary vascular disorders and is associated with a poor prognosis. Unlike treatments for left ventricular failure (LVF), strategies such as adrenoceptor signaling inhibition and renin-angiotensin system modulation have shown limited success in RVF.

View Article and Find Full Text PDF

Pro-Arg, The Potential Anti-Diabetes Peptide, Screened from Almond by In-Silico Analysis.

Plant Foods Hum Nutr

January 2025

College of Biology and Food Engineering, Chongqing Three Gorges University, Chongqing, 404100, China.

Insulin resistance was considered to be the most important clinical phenotype of type 2 diabetes (T2DM). Almond is a widely-consumed nut and long-term intake was beneficial to alleviating insulin resistance in patients with T2DM. Hence, screening of anti-diabetic peptides from almond proteins was feasible based on the effectiveness of peptides in the treatment of T2DM.

View Article and Find Full Text PDF

Palmitate potentiates the SMAD3-PAI-1 pathway by reducing nuclear GDF15 levels.

Cell Mol Life Sci

January 2025

Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Unitat de Farmacologia, Universitat de Barcelona, Av. Joan XXIII 27-31, 08028, Barcelona, Spain.

Nuclear growth differentiation factor 15 (GDF15) reduces the binding of the mothers' against decapentaplegic homolog (SMAD) complex to its DNA-binding elements. However, the stimuli that control this process are unknown. Here, we examined whether saturated fatty acids (FA), particularly palmitate, regulate nuclear GDF15 levels and the activation of the SMAD3 pathway in human skeletal myotubes and mouse skeletal muscle, where most insulin-stimulated glucose use occurs in the whole organism.

View Article and Find Full Text PDF

With the global rise in advanced maternal age (AMA) pregnancies, the risk of gestational diabetes mellitus (GDM) increases. However, few GDM prediction models are tailored for AMA women. This study aims to develop a practical risk prediction model for GDM in AMA women.

View Article and Find Full Text PDF

[Research advances in maturity-onset diabetes of the young].

Zhongguo Dang Dai Er Ke Za Zhi

January 2025

Department of Endocrine, Genetics and Metabolism, Children's Hospital Affiliated to Xi'an Jiaotong University, Xi'an 710003, China.

Maturity-onset diabetes of the young (MODY) is a special type of diabetes characterized by clinical features including early onset of diabetes (before 30 years of age), autosomal dominant inheritance, impaired glucose-induced insulin secretion, and hyperglycemia. So far, 14 types of MODY have been reported, accounting for about 1%-5% of the patients with diabetes. MODY often presents with an insidious onset, and although 14 subtypes have been identified for MODY, it is frequently misdiagnosed as type 1 or type 2 diabetes due to overlapping clinical features and high costs and limitations of genetic testing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!